CSL (CSL) Stock Price, News & Analysis

Company Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 869,289 shs
• Average Volume: N/A
• Market Capitalization: A$77.43 billion
• P/E Ratio: 28.02
• Dividend Yield: 1.56%
• Price Target: N/A
• Consensus Rating: N/A

CSL Stock Analysis - Frequently Asked Questions

How were CSL's earnings last quarter?

CSL Limited (ASX:CSL) released its quarterly earnings data on Wednesday, August, 14th. The company reported $4.24 earnings per share for the quarter, beating the consensus estimate of $4.22 by $0.01. CSL had a trailing twelve-month return on equity of 15.37% and a net margin of 18.41%.

What other stocks do shareholders of CSL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CSL investors own include Cochlear (COH), Mineral Resources (MIN), ResMed (RMD), Magellan Financial Group (MFG), NIB (NHF), Accent Group (AX1) and Corporate Travel Management (CTD).

Company Calendar

• Last Earnings: 8/14/2019
• Today: 8/03/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Rubber And Plastic Products
• Current Symbol: ASX:CSL
• CIK: N/A
• Web: www.csl.com.au
• Phone: +61-3-93891911
• Fax: N/A
• Employees: 12,500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A$7.88
• Trailing P/E Ratio: 28.02
• Forward P/E Ratio: N/A
• P/E Growth: 1.29
• Net Income: A$2.64 billion
• Net Margins: 18.41%
• Pretax Margin: N/A
• Return on Equity: 15.37%
• Return on Assets: 6.56%

Debt

• Debt-to-Equity Ratio: 64.46
• Current Ratio: 1.86
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: A$14.80 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 207.70
• Book Value: A$42.52 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 484,210,000
• Free Float: N/A
• Market Cap: A$77.43 billion
• Optionable: Not Optionable
• Beta: 0.32